NEW YORK (GenomeWeb News) – Response Genetics reported after the close of the market Thursday that its second-quarter revenues increased 4 percent on strong sales growth for its ResponseDx pharmacogenomic tests.

The Los Angeles-based firm reported total revenues of $1.9 million for the three-month period ended June 30, up from $1.8 million for the second quarter of 2008. It said that sales of its ResponseDx genetic tests increased 70 percent from the previous quarter to a total of $446,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.